Clinical trials in Caen – page 8

659 clinical trials in Caen, France across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Caen at a glance

659

clinical trials

Research sites3

Quick filters

659 trials in Caen

Open in trial search

HER2 positive breast cancer

Recruiting

Study evaluating HER2DX-guided treatment in patients with early-stage HER2-positive breast cancer using trastuzumab, pertuzumab and combination chemotherapy

Registered drugNo placebo

Study evaluating HER2DX-guided treatment in patients with early-stage HER2-positive breast cancer using trastuzumab, pertuzumab and combination chemotherapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer

Contact Research Centre

Gastric cancer stage IV+1

Recruiting

Study of ivonescimab with chemotherapy combination for first and second-line treatment in patients with advanced or metastatic gastric and gastroesophageal cancer

Registered drugNo placebo

Study of ivonescimab with chemotherapy combination for first and second-line treatment in patients with advanced or metastatic gastric and gastroesophageal cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Calcium Levofolinate
Sponsor:Unicancer

Contact Research Centre

Polymyalgia rheumatica

Recruiting

Study of baricitinib versus placebo for treating polymyalgia rheumatica in adult patients

Registered drug

Study of baricitinib versus placebo for treating polymyalgia rheumatica in adult patients

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Baricitinib
Sponsor:Centre Hospitalier Regional Et Universitaire De Brest

Contact Research Centre

Autoimmune haemolytic anaemia

Recruiting

Study of rilzabrutinib tablets compared to placebo in adults with warm autoimmune hemolytic anemia

Investigational

Study of rilzabrutinib tablets compared to placebo in adults with warm autoimmune hemolytic anemia

Investigational

France

Participants:18–64 years · 65+ years
Substances:Rilzabrutinib
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Clear cell renal cell carcinoma

Recruiting

Study of Lutetium-177-PSMA treatment for patients with advanced clear cell kidney cancer who had progression after first or second line therapy

Registered drugNo placebo

Study of Lutetium-177-PSMA treatment for patients with advanced clear cell kidney cancer who had progression after first or second line therapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Lutetium (177LU) vipivotide tetraxetan
Sponsor:European Organisation For Research And Treatment Of Cancer

Contact Research Centre

K-ras gene mutation+1

Recruiting

Study of MK-1084, cetuximab and mFOLFOX6 combination compared to mFOLFOX6 with or without bevacizumab for patients with KRAS G12C-mutant advanced colorectal cancer

Registered drugNo placebo

Study of MK-1084, cetuximab and mFOLFOX6 combination compared to mFOLFOX6 with or without bevacizumab for patients with KRAS G12C-mutant advanced colorectal cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Fallopian tube cancer+1

Recruiting

Study of mirvetuximab soravtansine dosing schedules for patients with platinum-resistant advanced ovarian, peritoneal, or fallopian tube cancer with high folate receptor expression

Registered drugNo placebo

Study of mirvetuximab soravtansine dosing schedules for patients with platinum-resistant advanced ovarian, peritoneal, or fallopian tube cancer with high folate receptor expression

Registered drugNo placebo

France

Participants:18–64 years
Substances:Prednisolone Acetate
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Transitional cell carcinoma

Recruiting

Study of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment

Registered drugNo placebo

Study of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Gastroenteropancreatic neuroendocrine tumour disease+1

Recruiting

Comparing tarlatamab with standard chemotherapy in patients with pre-treated advanced pulmonary or gastroenteropancreatic neuroendocrine carcinomas

Registered drugNo placebo

Comparing tarlatamab with standard chemotherapy in patients with pre-treated advanced pulmonary or gastroenteropancreatic neuroendocrine carcinomas

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Contact Research Centre

Haematological malignancy

Recruiting

Study of Reduced Cyclophosphamide Dose After Haploidentical Stem Cell Transplantation in Patients with Blood Cancer

Registered drugNo placebo

Study of Reduced Cyclophosphamide Dose After Haploidentical Stem Cell Transplantation in Patients with Blood Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Non-small cell lung cancer

Recruiting

Study of WSD0922-FU for Patients with Advanced Non-Small Cell Lung Cancer and C797S Mutation After Osimertinib Treatment

InvestigationalNo placebo

Study of WSD0922-FU for Patients with Advanced Non-Small Cell Lung Cancer and C797S Mutation After Osimertinib Treatment

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Sponsor:Wayshine Biopharm Inc.

Contact Research Centre

Hypertrophic cardiomyopathy

Recruiting

Study Evaluating Direct Oral Anticoagulants for Prevention of Blood Clots in Patients with Hypertrophic Cardiomyopathy and Abnormal Left Atrial Function

Registered drugNo placebo

Study Evaluating Direct Oral Anticoagulants for Prevention of Blood Clots in Patients with Hypertrophic Cardiomyopathy and Abnormal Left Atrial Function

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Rivaroxaban
Sponsor:Centre Hospitalier Universitaire De Rennes

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Caen

What the registry says about research in the country

01 Oncology Studies

Innovative research focusing on multiple cancer types including head and neck squamous cell carcinoma, endometrial cancer, and multiple myeloma. Studies evaluate novel therapeutic combinations and treatment strategies.

Advanced solid tumors
Hematological malignancies
Gastrointestinal cancers

Trials investigate targeted therapies and immunotherapy approaches for improved patient outcomes.

02 Infectious Disease Research

Studies examining prevention and treatment of respiratory infections, with focus on respiratory syncytial virus (RSV) in vulnerable populations. Investigation of novel antibiotics for prosthetic joint infections.

Viral infections
Bacterial infections
Preventive treatments

Research aims to develop effective preventive strategies and therapeutic interventions.

03 Cardiovascular Medicine

Research exploring treatments for heart failure prevention and management of cardiovascular conditions. Studies evaluate antiplatelet therapy strategies in elderly patients following interventional procedures.

Heart failure
Coronary interventions
Preventive cardiology

Focus on improving cardiovascular outcomes through innovative therapeutic approaches.

Back to France All countries